Payment overview · 2025
General Payments
$1,074.67
50 reported records · 15 companies
Healthcare provider profile · identity verified
Michael G Tsinman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WHEELING, IL · NPI 1710900907
Verified facts
What the public records show
CMS Open Payments records show Michael G Tsinman, M.D. received $1,074.67 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.21 | 16.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.28 | 14.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.15 | 13.3% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $92.78 | 8.6% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $90.07 | 8.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.64 | 7.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.07 | 6.9% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $59.88 | 5.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.35 | 4.2% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $35.80 | 3.3% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $31.32 | 2.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.86 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.92 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.33 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.01 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,074.67 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $122.75 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $122.75 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.44 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $94.79 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $92.78 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $90.07 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.64 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.07 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.07 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $59.88 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.46 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $47.71 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $45.35 | 2 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $35.80 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 79 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 129 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 221 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 132 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
132 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
131 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
221 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
221 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 87 |
| Omeprazole | Omeprazole | 352 | 72 |
| Lisinopril | Lisinopril | 350 | 82 |
| Metformin Hcl | Metformin Hcl | 338 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 328 | 87 |
| Famotidine | Famotidine | 258 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 47 |
| Eliquis | Apixaban | 230 | 37 |
| Jardiance | Empagliflozin | 221 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 205 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 58 |
| Benazepril Hcl | Benazepril Hcl | 197 | 47 |
| Allopurinol | Allopurinol | 177 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 36 |
| Spironolactone | Spironolactone | 157 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 37 |
| Nifedipine Er | Nifedipine | 151 | 32 |
| Simvastatin | Simvastatin | 150 | 29 |
| Furosemide | Furosemide | 141 | 30 |
| Atenolol | Atenolol | 137 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 55 |
| Linzess | Linaclotide | 132 | 26 |
| Losartan Potassium | Losartan Potassium | 131 | 39 |
| Synthroid | Levothyroxine Sodium | 131 | 17 |
| Farxiga | Dapagliflozin Propanediol | 129 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 22 |
| Glipizide | Glipizide | 124 | 29 |
| Gabapentin | Gabapentin | 123 | 42 |
| Ezetimibe | Ezetimibe | 118 | 23 |
| Alprazolam | Alprazolam | 97 | 21 |
| Carvedilol | Carvedilol | 97 | 26 |
| Valsartan | Valsartan | 97 | 16 |
| Potassium Chloride | Potassium Chloride | 96 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 14 |
| Lorazepam | Lorazepam | 92 | 17 |
| Ozempic | Semaglutide | 92 | 18 |
| Bumetanide | Bumetanide | 91 | 20 |
| Xarelto | Rivaroxaban | 91 | 11 |
| Zenpep | Lipase/Protease/Amylase | 91 | 15 |
| Memantine Hcl | Memantine Hcl | 89 | 18 |
| Hydrocortisone | Hydrocortisone | 87 | 20 |
| Enalapril Maleate | Enalapril Maleate | 83 | 16 |
| Meclizine Hcl | Meclizine Hcl | 81 | 23 |
| Creon | Lipase/Protease/Amylase | 79 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 26 |
| Finasteride | Finasteride | 77 | 15 |
| Vascepa | Icosapent Ethyl | 77 | 16 |
| Montelukast Sodium | Montelukast Sodium | 76 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 23 |
| Clonazepam | Clonazepam | 72 | 16 |
| Azithromycin | Azithromycin | 67 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 15 |
| Propranolol Hcl | Propranolol Hcl | 64 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | suppressed |
| Gemtesa | Vibegron | 61 | 16 |
| Mirtazapine | Mirtazapine | 59 | 16 |
| Glimepiride | Glimepiride | 58 | 18 |
| Januvia | Sitagliptin Phosphate | 58 | 12 |
| Acarbose | Acarbose | 57 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 55 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Procto-Med Hc | Hydrocortisone | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 40 | suppressed |
| Irbesartan | Irbesartan | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 17 |
| Nitroglycerin | Nitroglycerin | 39 | 14 |
| Lidocaine | Lidocaine | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 12 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 20 |
| Baclofen | Baclofen | 32 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 32 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 28 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | 12 |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 11 |
| Cephalexin | Cephalexin | 24 | 22 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 18 | 16 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Latanoprost | Latanoprost | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Restasis Multidose | Cyclosporine | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zioptan | Tafluprost/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,074.67 · 50 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, FARXIGA, Flector, GEMTESA, IBSRELA, JARDIANCE, KISUNLA, LEQVIO, LINZESS, Licart, MOUNJARO, OTEZLA, PREVNAR 20, QSYMIA, RECORLEV, REPATHA, Tirosint, UBRELVY, VOQUEZNA, Veozah, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error